Carmat (ALCAR) - Back on track as pivotal study resumes

06:22 EDT 31 Jul 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Carmat: Carmat resumed the EU pivotal trial of its artificial heart after addressing regulator concerns. We anticipate that the study could be completed in mid-2019, leading to a potential EU launch in 2020. The Carmat device could potentially fill a significant need among those waiting for human transplants and/or with terminal heart failure (HF) or acute myocardial infarction (MI). Our valuation is €627m, down from €747m previously.
ISIN: FR0010907956

Original Article: Carmat (ALCAR) - Back on track as pivotal study resumes


More From BioPortfolio on "Carmat (ALCAR) - Back on track as pivotal study resumes"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...